Vascular Biogenics Company Profile (NASDAQ:VBLT)

About Vascular Biogenics

Vascular Biogenics logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company is developing VB-111, the lead oncology product candidate from its VTS platform technology, which is a gene-based biologic for the treatment of solid tumor indications, with clinical programs in recurrent glioblastoma (rGBM), thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VBLT
  • CUSIP:
Key Metrics:
  • Previous Close: $4.03
  • 50 Day Moving Average: $4.08
  • 200 Day Moving Average: $3.76
  • 52-Week Range: $2.76 - $12.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.93
  • P/E Growth: 0.00
  • Market Cap: $95.12M
  • Outstanding Shares: 23,602,000
  • Beta: -3.52
Additional Links:
Companies Related to Vascular Biogenics:

Analyst Ratings

Consensus Ratings for Vascular Biogenics (NASDAQ:VBLT) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $15.50 (284.62% upside)

Analysts' Ratings History for Vascular Biogenics (NASDAQ:VBLT)
DateFirmActionRatingPrice TargetDetails
8/16/2016Roth CapitalReiterated RatingBuy$17.00View Rating Details
6/28/2016HC WainwrightInitiated CoverageBuy$11.00View Rating Details
6/7/2016Chardan CapitalReiterated RatingBuyView Rating Details
6/7/2016Piper Jaffray Cos.Reiterated RatingBuy$14.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00View Rating Details
11/13/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
1/22/2015Deutsche Bank AGBoost Price Target$12.00 -> $19.00View Rating Details
(Data available from 8/30/2014 forward)


Earnings History for Vascular Biogenics (NASDAQ:VBLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/15/2016Q2($0.23)($0.14)ViewListenView Earnings Details
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vascular Biogenics (NASDAQ:VBLT)
Current Year EPS Consensus Estimate: $-0.64 EPS
Next Year EPS Consensus Estimate: $-0.68 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)


Dividend History for Vascular Biogenics (NASDAQ:VBLT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Vascular Biogenics (NASDAQ:VBLT)
No insider trades for this company have been tracked by


Latest Headlines for Vascular Biogenics (NASDAQ:VBLT)
News IconShares Gapping Down Before the Open: Vascular Biogenics Ltd. (NASDAQ:VBLT) - Post News (NASDAQ:VBLT) - August 26 at 7:41 PM logoNew Report Available: Vascular Biogenics Ltd. (VBLT) - Financial and Strategic SWOT Analysis Review (NASDAQ:VBLT) - August 24 at 7:49 PM
News IconWHERE TO BUY VIAGRA - Buy Generic Viagra India (NASDAQ:VBLT) - August 22 at 8:00 PM logoWill Vascular Biogenics Ltd. (NASDAQ:VBLT) Hit $20 Price Target? - Investor Newswire (NASDAQ:VBLT) - August 20 at 7:33 PM
News IconCrowd Sentiment & Analyst Review on Vascular Biogenics Ltd. (NASDAQ:VBLT) - Post News (NASDAQ:VBLT) - August 20 at 11:43 AM logoVBL Therapeutics Announces Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:VBLT) - August 15 at 10:09 AM logoVascular Biogenics reports 2Q loss (NASDAQ:VBLT) - August 15 at 10:09 AM logoBioLineRx Names Philip A. Serlin as Chief Executive Officer (NASDAQ:VBLT) - August 11 at 11:33 AM logoVBL Therapeutics to Report Second Quarter 2016 Financial Results on August 15 (NASDAQ:VBLT) - July 26 at 8:38 AM
News IconVascular Biogenics Ltd. (NASDAQ:VBLT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:VBLT) - July 20 at 10:58 AM
News IconTrading Performance and Target Watch for Vascular Biogenics Ltd. (NASDAQ:VBLT) - Press Telegraph (NASDAQ:VBLT) - July 18 at 7:42 AM logoStrong Sell Calls For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire (NASDAQ:VBLT) - July 17 at 7:48 AM logoVascular Biogenics Ltd. (VBLT) Updated Price Targets - FTSE News (NASDAQ:VBLT) - July 14 at 11:45 AM
News IconAnalyst Target and Average Rating Watch: Vascular Biogenics Ltd. (NASDAQ:VBLT) - Press Telegraph (NASDAQ:VBLT) - July 13 at 8:25 PM logoIs $22 Within Reach For Vascular Biogenics Ltd. (NASDAQ:VBLT)? - Investor Newswire (NASDAQ:VBLT) - July 9 at 7:18 PM logoNew Broker Ratings For Vascular Biogenics Ltd. (VBLT) - FTSE News (NASDAQ:VBLT) - July 8 at 10:53 AM logoVascular Biogenics Ltd (NASDAQ:VBLT) target price raised to $11 as covered today by H.C. Wainwright - Breaking Finance News (NASDAQ:VBLT) - July 4 at 7:44 AM logoVascular Biogenics Ltd (NASDAQ:VBLT) target price raised to $11 as covered today by H.C. Wainwright (NASDAQ:VBLT) - July 3 at 7:13 PM logo7 Analyst Stock Picks Under $10 With Massive Upside Calls (NASDAQ:VBLT) - July 2 at 10:01 AM
News IconHC Stocks Growth: Vascular Biogenics Ltd (NASDAQ:VBLT), Clovis Oncology Inc (NASDAQ:CLVS) - share market updates (press release) (NASDAQ:VBLT) - July 1 at 10:44 AM logoCan Vascular Biogenics Ltd. (NASDAQ:VBLT) Meet Analysts Expectations? - Stocks Daily (NASDAQ:VBLT) - June 30 at 8:17 PM
News IconAnalyst Rating Update on Vascular Biogenics Ltd. (VBLT) - TheFounders Daily (NASDAQ:VBLT) - June 30 at 8:17 PM logoH.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics (NASDAQ:VBLT) - June 29 at 7:59 PM logoH.C. Wainwright Starts Vascular Biogenics Ltd (VBLT) at Buy - (NASDAQ:VBLT) - June 28 at 8:00 PM logoCoverage initiated on VBL Therapeutics by H.C. Wainwright (NASDAQ:VBLT) - June 28 at 7:07 AM logoHot Stocks: Neuralstem, Inc. (NASDAQ:CUR), Vascular Biogenics Ltd. (NASDAQ:VBLT), Accelerate Diagnostics, Inc ... - KC Register (NASDAQ:VBLT) - June 27 at 7:53 PM logoNext Weeks Broker Price Targets For Vascular Biogenics Ltd. (VBLT) - Fiscal Standard (NASDAQ:VBLT) - June 27 at 7:39 AM logoStrong Sell Calls Recommendations For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire (NASDAQ:VBLT) - June 26 at 7:38 AM
News IconVascular Biogenics Ltd. (NASDAQ:VBLT) Analyst Rating Consensus - TheFounders Daily (NASDAQ:VBLT) - June 22 at 7:46 AM logoVascular Biogenics Ltd. (VBLT) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:VBLT) - June 21 at 7:29 AM logoVBL Therapeutics Announces Appointment of Dr. Rachel W. Humphrey to Head of the Scientific Advisory Board (NASDAQ:VBLT) - June 21 at 7:19 AM logoVascular Biogenics Ltd. (VBLT) Current Analyst Ratings - Fiscal Standard (NASDAQ:VBLT) - June 17 at 10:45 AM logoVascular Biogenics Ltd. Closes $24 Million Registered Direct Offering (NASDAQ:VBLT) - June 16 at 12:49 PM
News IconStock's Earnings Analysis: STORE Capital Corporation (NYSE:STOR), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle (NASDAQ:VBLT) - June 13 at 11:03 AM logoInvestors Focused Stocks: Array BioPharma Inc. (NASDAQ:ARRY) , Vascular Biogenics Ltd. (NASDAQ:VBLT) - Street Updates (NASDAQ:VBLT) - June 10 at 11:12 AM
News IconEarnings Analysis to Watch: Brookdale Senior Living Inc. (NYSE:BKD), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle (NASDAQ:VBLT) - June 9 at 11:12 AM logoVascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:VBLT) - June 8 at 6:02 PM
News IconServices Stocks Try To Grab Potentials- Vascular Biogenics (NASDAQ:VBLT), Array BioPharma (NASDAQ:ARRY) - Seneca Globe (NASDAQ:VBLT) - June 7 at 8:22 PM logo8 Biggest Mid-Day Losers For Tuesday (NASDAQ:VBLT) - June 7 at 2:42 PM
News IconWorth Watching Stocks Roundup: Vascular Biogenics Ltd (NASDAQ:VBLT), Gerdau SA (ADR) (NYSE:GGB) - NYSE Journal (press release) (NASDAQ:VBLT) - June 7 at 10:58 AM logoWatch List - Cisco Systems, (NASDAQ:CSCO), Vascular Biogenics, (NASDAQ:VBLT) - Wall Street 24 (NASDAQ:VBLT) - June 7 at 10:58 AM logoVascular Biogenics Ltd (NASDAQ:VBLT) & ProNAi Therapeutics (NASDAQ:DNAI) Healthcare Stocks in the News - Wall Street 24 (NASDAQ:VBLT) - June 7 at 10:58 AM
News IconEarnings Overview: Globalstar Inc. (NYSEMKT:GSAT), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle (NASDAQ:VBLT) - June 7 at 10:58 AM logoVBL Therapeutics to Present Today at the 2016 BIO International Convention (NASDAQ:VBLT) - June 7 at 8:18 AM logoVascular Biogenics Surges 80% Off Double Catalyst - Benzinga (NASDAQ:VBLT) - June 6 at 8:15 PM logo9 Biggest Mid-Day Gainers For Monday (NASDAQ:VBLT) - June 6 at 1:42 PM logoVascular Biogenics Ltd (VBLT) Stock Roars Higher on Cancer Trial (NASDAQ:VBLT) - June 6 at 12:40 PM logoVascular Biogenics Ltd. (VBLT) Is Up Sharply On Study Results - RTT News (NASDAQ:VBLT) - June 6 at 12:15 PM logoWhy Vascular Biogenics Is One of the Biggest Winners From ASCO So Far (NASDAQ:VBLT) - June 6 at 8:55 AM logoVascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results (NASDAQ:VBLT) - June 6 at 8:40 AM


Vascular Biogenics (NASDAQ:VBLT) Chart for Tuesday, August, 30, 2016

Last Updated on 8/30/2016 by Staff